著者
竹馬 章悟 小川 竜一 越前 宏俊
出版者
Japanese Society of Drug Informatics
雑誌
医薬品情報学 (ISSN:13451464)
巻号頁・発行日
vol.17, no.4, pp.175-184, 2016 (Released:2016-03-19)
参考文献数
72

Objective: To evaluate the validity of dosage adjustment of renally eliminated drugs using Giusti and Hayton method in patients with renal dysfunction by reviewing the pharmacokinetic data of the drugs.Design: A systematic literature review.Methods: Drugs with the following characteristics: ≥70% of the drug excreted in urine is the unchanged form and ≥20% of the drug in plasma is the unbound drug, were retrieved from Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 12th edition.  For the drugs identified, the area under the concentration-time curves (AUC) obtained from pharmacokinetic studies in healthy subjects and patients with renal dysfunction were extracted from package inserts, interview forms, summary basis of approval, and by systematic review of the MEDLINE database.  Pharmacokinetic studies in children, patients with end-stage renal disease, patients on hemodialysis, and kidney transplanted patients were excluded from this review.  The observed AUC ratio (AUCRobserved) of a drug was calculated by dividing mean AUC of patients by that of healthy subjects, and stratified by creatinine clearance (CLcr) into three categories: 50 to 79 mL/min, 30 to 49 mL/min, and 10 to 29 mL/min.  Theoretical AUC ratios (AUCRpredicted) of drugs for the respective CLcr categories were calculated using Giusti and Hayton method.Results: Twenty-six drugs met our study criteria, and 43 data sets were obtained from the data sources.  The AUCRobserved deviated from the AUCRpredicted by more than ±50% in 3 of 35 (9%) data sets for CLcr 50 to 79 mL/min, 4 of 39 (10%) data sets for CLcr 30 to 49 mL/min, and 7 of 29 (24%) data sets for CLcr 10 to 29 mL/min.Conclusion: Since AUCRpredicted calculated by Giusti and Hayton method erratically over- or under-estimates the maintenance doses in patients with reduced renal function, the use of AUCRobserved is preferred for dose adjustment in these patients.

言及状況

外部データベース (DOI)

Twitter (8 users, 8 posts, 7 favorites)

@ph_minimal ↓になるかと思われます。 竹馬 章悟, 小川 竜一, 越前 宏俊, Giusti-Hayton法を用いた腎障害患者に対する腎消失型薬物の 用法・用量調節の妥当性に関する系統的文献調査研究, 医薬品情報学, 2015, 17 巻, 4 号, p. 175-184. https://t.co/YQ944mcwKW
【Giusti-Hayton法を用いた用量調節】 まだ自分なりに消化出来てないところ
【SY11】GH法は厳密にいうと腎CLというよりCrCl(≒GFR)を考慮しているので、相関するにしても分泌CLは考慮できていないのよね。なので、紹介されていた文献にもある通りアマンタジンとか大方分泌で除去される薬剤をESKDな患者さんで適用すると痛い目にあう。 #jsnp2020 https://t.co/ArtPyhZdIi
J-STAGE Articles - Giusti-Hayton法を用いた腎障害患者に対する腎消失型薬物の 用法・用量調節の妥当性に関する系統的文献調査研究 https://t.co/6UqvnlC4JD
https://t.co/CrrPDwXVk8 Guisti-Hayton法による用量補正は大部分の薬剤で妥当だが、高度腎機能低下者のGFRを395医薬品中24%の薬物で50%以上過大評価または過小評価した。これらの患者の投与量を調節する場合はできうる限り実測値を持ちうるべき。

収集済み URL リスト